iMediSync (www.imedisync.com) has developed an AI-driven early detection and therapeutic platform for optimal brain health. iMediSync launched its first solution to detect Mild Cognitive Impairment (early stage of Alzheimer’s Disease). iMediSync conducted the clinical trial with multicenter hospitals showing 90%+ accuracy for its solution. The vision of iMediSync, just like iSyncBrain MCI Classifier, is to develop early detecting biomarkers for challenging neurological disorders and diseases, such as COMA, Parkinson’s, ADHD, Depression and etc.

#Brainmapping #CES #DigitalHealth

свернуть